Investors
News Releases
- May 10, 2021Annovis Bio to Ring Closing Bell at the New York Stock Exchange
- May 6, 2021Annovis Bio Receives US Patent for Method of Treating Frontotemporal Dementia and Chronic Traumatic Encephalopathy
- April 29, 2021Annovis Bio to Study Potential of ANVS401 to Normalize Brain Development in Down Syndrome
- April 15, 2021Annovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman
- March 17, 2021Annovis Bio Presenting at M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
- March 16, 2021Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients
- March 11, 2021Annovis Bio Signs GMP Manufacturing Agreement to Support Planned Late- Stage Studies
- March 11, 2021Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit
- March 10, 2021Annovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury
- March 9, 2021Annovis Bio to Present at the H.C. Wainwright Global Life Sciences Conference
- May 4, 2022Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
- April 28, 2022Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
- April 11, 2022Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Media Coverage
Events & Presentations
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top